# Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

> **NCT00888173** · PHASE2 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 45 (actual)

## Conditions studied

- Endometrial Adenocarcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Mixed Adenocarcinoma
- Endometrial Mucinous Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Endometrial Squamous Cell Carcinoma
- Endometrial Transitional Cell Carcinoma
- Endometrial Undifferentiated Carcinoma
- Recurrent Uterine Corpus Carcinoma

## Interventions

- **DRUG:** Brivanib Alaninate
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00888173
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-06
- **Primary completion:** 2016-07-16
- **Final completion:** 2016-07-16
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00888173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00888173, "Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00888173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*